Given the human clinical experience with Xyotax since then, and the preclinical data Peter pointed to
Message 20930353
I'd say that despite the excretion, the drug must be accumulating in human tumor tissue somehow. Unless the animal models are really not close to human in a couple of respects. The distribution of drug in tissue would have to be different. Then, too, the preclinical data seems to directly contradict your assertion that it mostly excreted in original form in urine. Without seeing the data you can no longer find, it seems to me the simpler explanation is that at least some of the drug finds its way into tumor tissue and penetrates and kills it.
The only two explanations for the survival benefit we are apparently going to see are 1) the drug works, as per above, or 2) the placebo effect is huge. The longer the trial goes, the less plausible 2) seems.
OK, folks, fire at will. I have a fair interest in CTIC, so I'd be interested in a nice thorough SI debate to help me decide how to proceed. We can take it to the CTIC thread if it's starting to clutter this one.
Cheers, Tuck |
